aminopropionitrile has been researched along with Kidney Diseases in 1 studies
Aminopropionitrile: Reagent used as an intermediate in the manufacture of beta-alanine and pantothenic acid.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Since, LOX enzymes need copper (Cu) for their proper catalytic activity; the present study investigated the efficacy of a copper chelator, disulfiram (DSF) in renal fibrosis." | 8.12 | Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. ( Godugu, C; Kaki, VR; Saifi, MA; Shaikh, AS, 2022) |
| " Since, LOX enzymes need copper (Cu) for their proper catalytic activity; the present study investigated the efficacy of a copper chelator, disulfiram (DSF) in renal fibrosis." | 4.12 | Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. ( Godugu, C; Kaki, VR; Saifi, MA; Shaikh, AS, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saifi, MA | 1 |
| Shaikh, AS | 1 |
| Kaki, VR | 1 |
| Godugu, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram[NCT03212599] | 17 participants (Actual) | Observational | 2013-05-31 | Completed | |||
| A Randomized, Double-blind, Placebo-controlled Safety and Clinical Outcomes Study of Disulfiram in Subjects With Moderate COVID-19[NCT04594343] | Phase 2 | 140 participants (Actual) | Interventional | 2020-11-20 | Completed | ||
| A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma[NCT04521335] | Phase 1 | 2 participants (Actual) | Interventional | 2021-05-21 | Terminated (stopped due to Closed at PI's Request) | ||
| DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130] | Phase 2 | 11 participants (Actual) | Interventional | 2021-08-18 | Terminated (stopped due to Low COVID case numbers, competing COVID treatments available) | ||
| Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder[NCT02735577] | Phase 4 | 7 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | units on a scale (Median) |
|---|---|
| Cohort 1: Disulfiram | -2.60 |
| Cohort 1: Placebo | -2.14 |
Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | copies/mL (Mean) |
|---|---|
| Cohort 1: Disulfiram 1000 mg | -20.89 |
| Cohort 1: Placebo | -20 |
Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | fold change (Median) | |
|---|---|---|
| Change in IL-6 (pg/mL) Day 0 to 31 | Change in IL-1B (pg/mL) Day 0 to 31 | |
| Cohort 1: Disulfiram 100 mg | -0.1186 | -0.1402 |
| Cohort 1: Placebo | -0.0215 | 0.0268 |
The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE Grade 3 or Higher | AE Grade 1 or 2 | |
| Cohort 1: Disulfiram 1000 mg | 0 | 4 |
| Cohort 1: Placebo | 1 | 1 |
Number of drinking days (NCT02735577)
Timeframe: 42 days
| Intervention | days (Mean) |
|---|---|
| Disulfiram | 0 |
1 other study available for aminopropionitrile and Kidney Diseases
| Article | Year |
|---|---|
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |
Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes.
Topics: Aminopropionitrile; Animals; Collagen; Copper; Disulfiram; Fibrosis; Humans; Kidney Diseases; Protei | 2022 |